CBLL
CeriBell, Inc.
$19.14
-0.26
(-1.34%)
Mkt Cap
726.22M
Volume
525,242
52W Range
10.85-24.33
Sector
Healthcare
Beta
0.77
EPS (TTM)
-1.63
P/E Ratio
-15.02
Revenue (TTM)
95.07M
Rev Growth (5Y)
+50.9%
EPS Growth (5Y)
N/A
Company Description
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 89.06M | 65.44M | 45.23M | 25.92M |
| Net Income | (53.41M) | (40.45M) | (29.46M) | (37.16M) |
| EPS | -1.46 | -3.39 | -1.26 | -1.59 |
| Free Cash Flow | (41.58M) | (36.38M) | (30.14M) | (32.52M) |
| FCF / Share | -1.14 | -3.04 | -1.29 | -1.39 |
| Operating CF | (40.81M) | (35.04M) | (29.16M) | (32.00M) |
| Total Assets | 195.80M | 225.41M | 58.92M | 86.46M |
| Total Debt | 22.28M | 21.96M | 14.20M | 18.22M |
| Cash & Equiv | 40.48M | 194.37M | 34.49M | 68.23M |
| Book Value | 155.34M | 191.16M | (112.25M) | (86.40M) |
| Return on Equity | -0.34 | -0.21 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.49M | 24.78M | 22.59M | 21.20M | 20.49M | 18.53M | 17.20M | 14.86M | 14.86M | 13.13M | 11.61M | 10.24M |
| Net Income | (19.74M) | (13.53M) | (13.46M) | (13.64M) | (12.78M) | (12.58M) | (10.42M) | (8.73M) | (8.73M) | (8.27M) | (7.05M) | (7.07M) |
| EPS | -0.52 | -0.36 | -0.37 | -0.38 | -0.36 | -0.40 | -0.31 | -1.59 | -1.59 | 1.74 | -0.30 | -1.35 |
| Free Cash Flow | (20.12M) | (10.95M) | (11.47M) | (7.60M) | (11.68M) | (10.33M) | (9.11M) | (7.26M) | (9.68M) | (7.36M) | (7.58M) | (8.22M) |
| FCF / Share | -0.53 | -0.29 | -0.31 | -0.21 | -0.33 | -0.33 | -0.27 | -1.32 | -1.76 | -0.32 | -0.33 | -1.57 |
| Operating CF | (19.30M) | (10.77M) | (11.10M) | (7.53M) | (11.40M) | (9.97M) | (8.54M) | (6.98M) | (9.55M) | (6.67M) | (7.43M) | (7.53M) |
| Total Assets | 178.08M | 195.80M | 199.53M | 207.69M | 213.47M | 225.41M | 47.06M | 53.18M | 0 | 58.92M | N/A | N/A |
| Total Debt | 22.12M | 22.28M | 21.34M | 21.55M | 21.76M | 21.96M | 22.12M | 22.22M | 0 | 14.20M | N/A | N/A |
| Cash & Equiv | 45.25M | 40.48M | 23.74M | 40.14M | 153.36M | 194.37M | 14.11M | 24.36M | 0 | 34.49M | N/A | N/A |
| Book Value | 140.81M | 155.34M | 164.08M | 172.16M | 180.88M | 191.16M | (135.98M) | (127.28M) | 35.16M | (112.25M) | N/A | N/A |
| Return on Equity | -0.14 | -0.09 | -0.08 | -0.08 | -0.07 | -0.07 | N/A | N/A | -0.25 | N/A | N/A | N/A |
CBLL News
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell Q1 Earnings Call Highlights
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
Ceribell Reports First Quarter 2026 Financial Results
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026